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ABSTRACT
Caspases and granzyme B are proteases that share
the primary specificity to cleave at the carboxyl ter-
minal of aspartate residues in their substrates. Both,
caspases and granzyme B are enzymes that are
involved in fundamental cellular processes and play
acentralroleinapoptoticcelldeath.Althoughvarious
targets are described, many substrates still await
identification and many cleavage sites of known sub-
strates are not identified or experimentally verified.
A more comprehensive knowledge of caspase and
granzyme B substrates is essential to understand
the biological roles of these enzymes in more detail.
The relatively high variability in cleavage site recog-
nition sequence often complicates the identification
of cleavage sites. As of yet there is no software avail-
ablethatallowsidentificationofcaspaseand/orgran-
zymewithcleavagesitesdifferingfromtheconsensus
sequence. Here, we present a bioinformatics tool
‘GraBCas’ that provides score-based prediction of
potential cleavage sites for the caspases 1–9 and
granzyme B including an estimation of the fragment
size.WetestedGraBCasonalreadyknownsubstrates
and showed its usefulness for protein sequence




Caspases are enzymes orchestrating the cellular pathways
leading to apoptosis and inﬂammatory signals. Besides
these functions they are supposed to be involved in other
cellular processes, such as development, cell cycle, cell
proliferation, cell migration and receptor internalization
(1,2). Caspases are cysteine proteases with speciﬁcity for
an aspartic acid residue at position P1 of the substrate.
This primary speciﬁcity is shared by the serine protease gran-
zyme B, which induces cytotoxic T lymphocyte-mediated
target cell DNA fragmentation and apoptosis (3,4). Granzyme
B-mediated cleavage also plays a role in induction of
autoimmunity (5).
To date, at least 14 mammalian caspases can be grouped
into three classes based on their substrate speciﬁcities. Group I
consisting of caspases -1, -4, -5 (-14 and murine -11 and -12)
cleaves the substrate sequence (W/L)EHD, group II (caspases
-2,-3,-7)cleavestheDEXDmotifandgroupIII(caspase-6,-8,
-9, -10) preferentially cleaves the (L/V)E(T/H)D sequence
(6,7). Caspases of group I play an important role in the gen-
eration of inﬂammatory signals and in the immune regulation.
Caspases -8, -9 and -10 are so-called initiator caspases mainly
cleaving and activating procaspases, whereas caspases -3, -6
and -7 as effector caspases cleave numerous cellular proteins.
The serine protease granzyme B prefers substrates with
sequence IEXD, and is released by cytotoxic lymphocytes
to kill virus-infected or tumor cells.
Although more than 280 caspase targets are described [for
comprehensive review see (8)] many substrates still await
identiﬁcation and many cleavage sites of known substrates
are not identiﬁed or experimentally veriﬁed. Likewise, the
identiﬁcation of granzyme B substrates is still at its infancy.
Intracellular substrates of granzyme B include other caspases,
mainly caspase 3 (9), ADPRT (ADP-ribosyltransferase 1,
PARP) (10), BID (BH3 interacting domain death agonist)
(11) and ICAD (DNA fragmentation factor) (12). Notably,
the majority of autoantigens in systemic autoimmune diseases
are efﬁciently cleaved by granzyme B (5).
A more comprehensive knowledge of caspase and gran-
zyme B substrates is essential to understand the biological
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variability in cleavage site recognition sequence often com-
plicates the identiﬁcation of cleavage sites. As of yet there is
no software available that allows identiﬁcation of caspase and/
or granzyme cleavage sites differing from the consensus
sequence. The PeptidCutter program provided by the ExPasy
Server (http://www.expasy.org/tools/peptidecutter) considers
only the preferred peptide substrate sites. A recent tool of
Lohmu ¨ller et al. (13) is restricted to caspase 3 and cathepsin
B and -L substrates. Here, we present a bioinformatics tool
GraBCas that provides score-based prediction of potential
cleavage sites for the caspases 1–9 and granzyme B including
an estimation of the fragment size. We validated our tool by
scoring known substrates and demonstrated its usefulness for
protein sequence analysis.
MATERIALS AND METHODS
Design of cleavage site scoring matrices
We developed position speciﬁc scoring matrices (PSSM) for
the endopeptidases granzyme Band caspase 1–9 based on exp-
erimentally determined substrate speciﬁcities (6). Thornbery
et al. (6) determined the substrate speciﬁcities using positional
scanning synthetic combinatorial libraries. Cleavage was ﬂu-
orimetrically determined with maximum value annotated with
100 and the values for the remaining amino acids given as
percentageoftheobservedmaximumrate.Theseexperimental
values provided the basis for creating our PSSM.
The values for each amino acid at position Pi are shown in
Table 1. For a better readability we decided to set the max-
imum values to 1000 instead of 100 and adjusted the other
values accordingly. For each endopeptidase the scores of the
amino acids were entered in a 3 · 20 matrix. The rows of such
a matrix correspond to positions P4, P3 or P2 of a possible
cleavage site. Each column represents one amino acid and
contains the relative frequencies of the amino acid measured
in the study of Thornbery et al. (6). We are working with
PSSM that can be interpreted as probability matrices. Since
probabilities of value 0 should be avoided in such probability-
based position scores, all entries of experimental relative fre-
quencies with value 0 were set to 1. The amino acids cysteine
and methionine were not part of the study of Thornbery et al.
(6). The entries for these amino acids were also set to 1 in
Table 1.
Computing the scores of endopeptidase cleavage sites
For computing the score, the GraBCas program screens for
tetrapeptides with Asp (D) at their last position (P1) in a given
amino acid sequence. Given the tetrapeptide A4A3A2D
( P4P3P2P1) of a potential cleavage site, its score for a
given endopeptidase is computed by multiplying the corres-
ponding matrix entries of A2 at position P2, A3 at position P3
and A4 at position P4. The product is divided by the value







C ST P AGND E QH RKM I L V FYW
Granzyme B 4 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1000 52 500 12 1 1
3 E 1 297 54 1 153 477 1 198 1000 81 9 1 1 1 1 1 1 1 1 9
2 P 1 752 544 1000 576 16 624 144 288 576 544 1 1 1 16 96 304 144 16 16
Caspase 1 4 W 1 48 48 48 48 16 16 80 96 16 128 1 1 1 96 288 80 496 576 1000
3 E 1 357 442 1 442 425 119 374 1000 646 187 51 34 1 221 323 442 272 187 85
2 H 1 144 396 144 180 18 72 36 72 108 1000 54 72 1 198 54 108 126 144 126
Caspase 2 4 D 1 1 50 10 1 1 10 1000 200 1 1 1 1 1 180 400 80 40 40 1
3 E 1 425 884 1 680 119 119 102 1000 680 153 408 221 1 119 187 646 255 187 153
2 H 1 624 528 352 336 48 96 1 1 16 1000 320 304 1 144 16 80 16 16 80
Caspase 3 4 D 1 40 50 1 10 1 20 1000 40 1 10 1 1 1 10 1 20 10 1 1
3 E 1 306 357 1 357 85 153 255 1000 408 187 17 17 1 153 153 306 272 255 119
2 V 1 14 378 406 182 1 14 1 0 14 196 42 0 1 714 224 1000 182 154 84
Caspase 4 4 W 1 80 208 144 96 48 80 288 256 96 48 1 1 1 304 848 224 384 352 1000
3 E 1 187 119 34 119 17 85 221 1000 306 85 1 17 1 51 85 204 187 85 17
2 H 1 102 119 119 425 17 102 221 357 153 1000 51 1 1 595 17 119 85 102 51
Caspase 5 4 W 1 14 56 1 56 126 42 98 98 84 56 1 1 1 280 1000 154 504 406 1000
3 E 1 24 12 1 12 1 1 124 1000 12 12 1 1 1 12 12 12 12 12 1
2 H 1 340 425 323 323 1 85 119 323 85 1000 17 34 1 272 17 272 153 204 102
Caspase 6 4 V 1 144 880 64 96 16 64 224 256 48 48 1 1 1 656 304 1000 80 48 48
3 E 1 48 48 16 80 16 16 176 1000 144 48 1 1 1 16 16 48 48 16 48
2 H 1 54 576 18 72 18 108 18 18 36 1000 54 36 1 648 486 918 288 216 558
Caspase 7 4 D 1 117 78 1 39 26 26 1000 104 26 39 1 1 1 13 1 13 13 13 1
3 E 1 221 357 1 323 51 153 255 1000 425 187 85 102 1 306 221 697 204 204 102
2 V 1 16 448 448 128 16 48 1 1 16 208 80 16 1 704 176 1000 160 128 48
Caspase 8 4 L 1 208 304 480 448 96 304 704 448 96 144 1 1 1 576 1000 720 224 256 144
3 E 1 45 75 0 45 15 15 180 1000 150 45 1 1 1 45 15 105 45 45 15
2 T 1 180 1000 216 324 18 126 72 198 108 306 72 72 1 720 108 792 180 198 306
Caspase 9 4 L 1 198 216 594 576 144 108 414 468 180 126 36 18 1 576 1000 684 252 216 144
3 E 1 85 136 51 85 17 17 272 1000 187 119 1 17 1 102 119 204 102 85 51
2 H 1 85 136 102 85 17 17 51 34 17 1000 34 1 1 187 17 153 51 34 51
Amino acid preference distribution for each position Pi was extracted from Thornberry et al. (6) giving the most common amino acid a value of 1000.
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3) of the product of the consensus recognition motif for
normalization and multiplied by 100, yielding a total score
between 0 and 100.
Score A4A3A2D ðÞ
¼ 100 ·
ScoreP4 A4 ðÞ · ScoreP3 A3 ðÞ · ScoreP2 A2 ðÞ
10003 :
Using additional ﬁlter options for granzyme B and
caspase 3
To improve the power of the prediction we analyzed the amino
acid distribution of known granzyme B and caspase 3 cleavage
sites at positions P6–P20 taken from the literature (see also
Supplementary Material 1 and 2).
For granzyme B we found a preference for V (15·) and
I (11·) at position P4, for E (9·) at position P3 and for P (11·)
at position P2 in accordance with the results of Thornberry
et al. (6). We detected S at position P10 and G at position P20,
respectively in 9 out of 30 cleavage sites. The result list of the
PSSM-based cleavage sites can optionally be ﬁltered with two
‘stringency’ ﬁlters that take the occurrence of amino acids at
position P20 into account. We installed a ‘low stringency’ ﬁlter
that excludes hits with the amino acids C, Q, I, M, V all of
which are medium sized or large amino acids. A second ‘high
stringency’ ﬁlter selects hits with a G at position P20.
The analysis of the 59 cleavage sites of caspase 3 substrate
conﬁrmed the preferences for D at P4 (31·), E at P3 (17·) and
VatP2(16·).ForP10 wefoundanabundanceofG(18·)andS
(17·) and in lower amount A (5·) and N (4·). As for the
granzyme B prediction, two additional ‘stringency’ ﬁlters
for the prediction of caspase 3 cleavage sites are available.
The ‘high stringency’ ﬁlter screens the predicted hits for
occurrences of G, S, A or N at position P10, and the ‘low
stringency’ ﬁlter screens for absence of R, E, H, K, Q, I, L,
M, F, W and Y at this position.
GraBCas software tool
The GraBCas program was written in Java
TM and is available
as an application or as an applet. Both are available at http://
wwwalt.med-rz.uniklinik-saarland.de/med_fak/humangenetik/
software/index.html. If your browser does not support Java
TM
you need to install the Java Runtime Environment (JRE) 1.4.x,
which can be downloaded at http://java.sun.com.
The graphical user interface is easy to use. There are several
register cards for each endopeptidase and one register card
presenting the input form, where the amino acid sequence can
be pasted and a cutoff for the PSSM scores can be chosen.
After pressing the OK-button in the input form, the program
calculates the scores of potential cleavage sites for all
endopeptidases and presents them in the corresponding regis-
ter card sorted with the highest scoring sites on top. The user
can open an additional window for viewing the positions of
the predicted cleavage sites within the amino acid sequence.
The window also shows the fragment length and size in kDa
(0.11 kDa per amino acid) of the predicted fragments.
As described above, for caspase 3 and granzyme B addi-
tional ﬁlter options are available in their register cards. The
two ﬁlter types for these enzymes, a ‘high-stringency’ and a
‘low-stringency’ ﬁlter, are based on the extended substrate
speciﬁcity. For granzyme B the amino acids at position P20
were taken into account in addition to the positions P4–P1. For
caspase 3, amino acids at position P10 are evaluated.
Sensitivity–specificity plots
For determining the speciﬁcity and sensitivity of the GraBCas
predictions we used the known cleavage sites of granzyme B
(4–6,9–12) summarized in Table 2 and the known non-
substrates of granzyme B (5) presented in Table 4. Due to
the lack of information on known non-substrates for caspase
3 the sensitivity–speciﬁcity plot could only be calculated for
granzyme B (Figure 1).
The x-axis of the plots represents the cutoff values (with
respect to the PSSM scores), while the y-axis represents the
percentage of the speciﬁcity or sensitivity of the predictions
made by GraBCas, respectively. The speciﬁcity is computed
as follows:
Number of true negatives
Number of false positives þ Number of true negatives
:
The true negatives are the known non-substrates where the
maximal PSSM score of all tetrapeptides ending with a D is
smaller than the chosen cutoff value. A speciﬁcity of 1 means
that all known non-substrates were below the cutoff, i.e. all
known non-substrates were correctly classiﬁed as negatives.
The sensitivity is deﬁned as:
Number of true positives
Number of true positives þ Number of false negatives
‚
where true positives are the known cleavage sites with a score
larger than the chosen cutoff value. A sensitivity of 1 means
that all cleavage sites of our test set (Table 2) have a score
higher than the chosen cutoff and that they have been correctly
classiﬁed as positives.
RESULTS AND DISCUSSION
We analyzed the cleavage sites of known substrates of
granzyme B and caspase 3 to compare the experimentally
identiﬁed peptide speciﬁcity with the cleavage site predicted
by the program GraBCas.
Intotal,we collected29substrates with 30 cleavage sites for
granzyme B (Table 2) and 47 substrates with 59 cleavage sites
for caspase 3 (Table 3) and computed the GraBCas scores of
the cleavage sites. For granzyme B we collected additionally
17 sequences which are non-substrates of this endopeptidase
(Table 4), computed the scores of all putative cleavage sites in
these sequences and extracted the best hit by GraBCas for each
of these non-substrates.
The sensitivity–speciﬁcity plot for granzyme B is shown
in Figure 1. When using a cutoff value of 1.2 in the
GraBCas program, we obtain a sensitivity of  80% and a
speciﬁcity of  82%. The cutoff value can be adjusted if a
higher speciﬁcity or sensitivity is needed for the cleavage site
prediction.
A closer look at the sensitivity–speciﬁcity plot shows that
the best score (28.8 for IEED in glycogen phosphorylase)
of the alleged non-substrates is extremely high. The top value
of the best hit IEED is due to the fact that this tetrapeptide has
three identical positions with the granzyme B consensus
W210 Nucleic Acids Research, 2005, Vol. 33, Web Server issuerecognition motif IEPD. Furthermore, the amino acid E on P2
has a middle-sized value and the tetrapeptides LEED, IEAD
and IETD are known substrates of granzyme B. We assume
that glycogen phosphorylase is probably a substrate of gran-




are based on these statistics. For granzyme B, we detected G at
position P20 in 9/30 cleavage sites. This conﬁrms the results of
Harris et al. (14), who found for recombinant rat granzyme B a
speciﬁcity for G at P20. We did not, however, conﬁrm the pro-
posed total absence of charged amino acids at P10, in that we
found E three times, R two times and K and D one time, each.
For caspase 3, we found in total 44/59 (75%) cleavage sites
with G, S, A or N at position P10. These results are in good
Table 2. Analysis of cleavage sites of known granzyme B substrates with GraBCas






AARS: alanyl-tRNA synthetase NP_001596 VADP (632) 7,65 SLVAPDRL
ADPRT: ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase) NP_001609 VDPD (536) 9,9 AAVDPDSG
BID: BH3 interacting domain death agonist NP_001187 IEAD (75) 57,6 GRIEADSE
CASP3: caspase 3, apoptosis-related cysteine protease NP_004337 IETD (175) 54,4 CGIETDSG
CASP7: caspase 7, apoptosis-related cysteine protease NP_001218 IQAD (198) 4,6656 DGIQADSG
CENPB: centromere protein B, 80 kDa NP_001801 VDSD (457) 7,4448 GDVDSDEE
CHD4: chromodomain helicase DNA binding protein 4 NP_001264 VDPD (1312) 9,9 ESVDPDYW
DFFA: DNA fragmentation factor, 45 kDa, alpha polypeptide NP_004392 DETD (117) 0,0544 MEVTGDAG
DFFA: DNA fragmentation factor, 45 kDa, alpha polypeptide NP_004392 VTGD (6) 0,0432 DVDETDSG
FBL: fibrillarin NP_001427 VGPD (184) 23,85 DIVGPDGL
FLNA: filamin A, alpha (actin binding protein 280) NP_001447 ? 11,4048 TEIDQDKY
G22P1: thyroid autoantigen 70 kDa (Ku antigen) NP_001460 ISSD (79) 22,3344 KIISSDRD
GRIA3: glutamate receptor, ionotrophic, AMPA 3 NP_000819 ISND (416) 18,5328 QQISNDSA
HARS: histidyl-tRNA synthetase NP_002100 LGPD (48) 2,4804 AQLGPDES
IARS: isoleucine-tRNA synthetase NP_002152 VTPD (983) 2,7 LDVTPDQS
L4 100K [Human adenovirus C] AAQ19301 IEQD (48) 57,6 VIIEQDPG
MKI67: antigen identified by monoclonal antibody Ki-67 NP_002408 VCTD (1481) 0,0272 TPVCTDKP
NUMA1: nuclear mitotic apparatus protein 1 NP_006176 VATD (1705) 4,1616 FQVATDAL
PMS1: PMS1 postmeiotic segregation increased 1 NP_000525 ISAD (496) 17,1072 SEISADEW
PMS2: PMS2 postmeiotic segregation increased 2 NP_000526 VEKD (493) 0,05 AEVEKDSG
PMSCL2: polymyositis/scleroderma autoantigen 2, 100 kDa NP_002676 VEQD (252) 28,8 QQVEQDMF
POLR1A: polymerase (RNA) I polypeptide A, 194 kDa NP_056240 ICPD (448) 0,1 SVICPDMY
POLR2A: polymerase (RNA) II (DNA directed) polypeptide A, 220 kDa NP_000928 ITPD (370) 5,4 TVITPDPN
PRKDC: protein kinase, DNA-activated, catalytic polypeptide NP_008835 VGPD (2698) 23,85 KSVGPDFG
SNRP70: small nuclear ribonucleoprotein 70 kDa polypeptide (RNP antigen) NP_003080 LGND (409) 1,5477696 EGLGNDSR
SRP72: signal recognition particle 72 kDa NP_008878 VTPD (573) 2,7 PKVTPDPE
SSB: Sjogren syndrome antigen B (autoantigen La) NP_003133 LEED (220) 1,4976 QKLEEDAE
TOP1: topoisomerase (DNA) I NP_003277 IEAD (15) 57,6 SQIEADFR
UBE4B: ubiquitination factor E4B (UFD2 homolog, yeast) NP_006039 VDVD (123) 3,0096 SQVDVDSG
UBTF: upstream binding transcription factor, RNA polymerase I NP_055048 VRPD (220) 0,05 LKVRPDAT
The bold printed amino acids in the extended cleavage site indicate hits with a G residue at position P20 detected by the high stringency filter. Numbers in brackets
indicate cleavage site position in the amino acid sequence.
Figure 1. Sensitivity–specificity plot for granzyme B. x-axis: scores by the GraBCas program; y-axis: percentage of specificity or sensitivity.
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ADD1: adducing 1 (alpha) NP_001110 DDSD (633) 0,357 TGDDSDAA
APAF1: apoptotic protease activating factor NP_001151 SVTD (271) 0,462672 DKSVTDSV
ARHGDIB: Rho GDP dissociation inhibitor (GDI) beta NP_001166 DELD (19) 22,4 DDDELDSK
ATP2B4: ATPase, Ca++ transporting, plasma membrane 4 NP_001675 DEID (1080) 71,4 GLDEIDHA
BAD: BCL2-antagonist of cell death NP_004313 EQED (14) 0,001632 PSEQEDSS
BAX: BCL2-associated X protein NP_004315 FIQD (33) 0,002142 QGFIQDRA
BCL2: B-cell CLL/lymphoma 2 NP_000624 DAGD (34) 0,0357 EWDAGDVG
BCL2L1: BCL2-like 1 NP_001182 HLAD (61) 0,027846 SWHLADSP
BCL2L1: BCL2-like 2 NP_001182 SSLD (76) 0,274176 HSSSLDAR
BIRC2: baculoviral IAP repeat-containing 2 NP_001157 ENAD (372) 0,111384 GEENADPP
BLM: Bloom syndrome NP_000048 TEVD (415) 5 LLTEVDFN
BRCA1: breast cancer 1, early onset NP_009225 DLLD (1154) 3,4272 PDDLLDDG
CAMK4: calcium/calmodulin-dependent protein kinase IV NP_001735 YWID (31) 0,0084966 PDYWIDGS
CAMK4: calcium/calmodulin-dependent protein kinase IV NP_001735 PAPD (176) 0,0144942 ATPAPDAP
CDC2L1: cell division cycle 2-like 1 (PITSLRE proteins) NP_001778 YVPD (391) 0,0124236 GDYVPDSP
CDC6: CDC6 cell division cycle 6 homolog
(Saccharomyces cerevisiae)
NP_001245 SEVD (442) 4 VISEVDGN
CDC6: CDC6 cell division cycle 6 homolog (S.cerevisiae) NP_001245 LVRD (99) 0,0055692 RRLVFDNQ
CDKN1A: cyclin-dependent kinase inhibitor 1A (p21, Cip1) NP_000380 DHVD (112) 18,7 EEDHVDLS
CSEN: calsenilin, presenilin binding protein, EF hand transcription factor NP_038462 DSSD (64) 0,4284 GSDSSDSE
CTNNB1: catenin (cadherin-associated protein), beta 1, 88 kDa NP_001895 DLMD (764) 0,0153 AQDLMDGL
CTNNB1: catenin (cadherin-associated protein), beta 1, 88 kDa NP_001895 YPVD (751) 10 ADYPVDGL
CTNNB1: catenin (cadherin-associated protein), beta 1, 88 kDa NP_001895 ADID (83) 0,18207 QVADIDGQ
CTNNB1: catenin (cadherin-associated protein), beta 1, 88 kDa NP_001895 TQFD (115) 0,37128 PSTQFDAA
CTNNB1: catenin (cadherin-associated protein), beta 1, 88 kDa NP_001895 SYLD (32) 0,22848 QQSYLDSG
DFFA: DNA fragmentation factor, 45 kDa, alpha polypeptide NP_004392 DAVD (224) 35,7 EVDAVDTG
DFFA: DNA fragmentation factor, 45 kDa, alpha polypeptide NP_004392 DETD (117) 37,8 DVDETDSG
DRPLA: dentatorubral-pallidoluysian atrophy (atrophin-1) NP_001931 DSLD (109) 6,8544 DLDSLDGR
EIF2S1: eukaryotic translation initiation factor 2,
subunit 1 alpha, 35 kDa
NP_004085 AEVD (301) 1 ENAEVDGD
EIF2S1: eukaryotic translation initiation factor 2, subunit 1 alpha, 35 kDa NP_004085 DGDD (304) 0,0085 EVDGDDDA
FNTA: farnesyltransferase, CAAX box, alpha NP_002018 VSLD (59) 0,137088 GFVSLDSP
GCLC: glutamate-cysteine ligase, catalytic subunit NP_001489 AVVD (499) 0,306 GNAVVDGC
GSN: gelsolin (amyloidosis, Finnish type) NP_000168 DQTD (403) 15,4224 DPDQTDGL
HD: huntingtin (Huntington disease) NP_002102 DSVD (513) 30,6 WEAQRDSH
HNRPU: heterogeneous nuclear ribonucleoprotein U
(scaffold attachment factor A)
NP_004492 SALD (100) 0,319872 GISALDGD
IL16: interleukin 16 (lymphocyte chemoattractant factor) NP_004504 SSTD (510) 0,462672 LNSSTDSA
IL18: interleukin 18 (interferon-gamma-inducing factor) NP_001553 LESD (36) 0,0014 ENLESDYF
KRT18: keratin 18 NP_000215 VEVD (238) 2 LTVEVDAP
MAPT: microtubule-associated protein tau NP_005901 DMVD (421) 0,1 SIDMVDSP
MDM2: Mdm2, transformed 3T3 cell double minute 2,
p53 binding protein (mouse)
NP_002383 DVPD (361) 12,4236 GFDVPDCK
NFKBIA: nuclear factor of kappa light polypeptide gene enhancer
in B-cells inhibitor, alpha
NP_065390 DRHD (32) 0,3332 LDDRHDSG
NUMA1: nuclear mitotic apparatus protein 1 NP_006176 DSLD (1712) 6,8544 SIDSLDLS
PAK2: p21 (CDKN1A)-activated kinase 2 NP_002568 SHVD (212) 0,748 GDSHVDGA
POLE: polymerase (DNA directed), epsilon NP_006222 DQLD (189) 9,1392 IADQLDNI
POLE: polymerase (DNA directed), epsilon NP_006222 DMED (1185) 10 APDMEDFG
PPP2R1A: protein phosphatase 2 (formerly 2A), regulatory subunit
A (PR 65), alpha isoform
NP_055040 DEQD (218) 1,4 ASDEQDSV
PRKCD: protein kinase C, delta NP_006245 DMQD (329) 0,0014 GEDMQDNS
PRKCM: protein kinase C, mu NP_002733 CQND (378) 5,712 AECQNDSG
PRKCQ: protein kinase C, theta NP_006248 DEVD (354) 100 PLDEVDKM
PRKCZ: protein kinase C, zeta NP_002735 DGVD (239) 0,0085 VIDGMDGI
PRKCZ: protein kinase C, zeta NP_002735 EETD (210) 1,512 PSEETDGI
PRKDC: protein kinase, DNA-activated, catalytic polypeptide NP_008835 DEVD (2713) 100 PGDEVDNK
PSEN2: presenilin 2 (Alzheimer disease 4) NP_000438 DSYD (329) 4,7124 EEDSYDSF
RB1: retinoblastoma 1 (including osteosarcoma) NP_000312 DEAD (886) 18,2 GSDEADGS
RFC1: replication factor C (activator 1) 1, 145 kDa NP_002904 DEVD (722) 100 IMDEVDGM
ROCK1: Rho-associated, coiled-coil containing protein kinase 1 NP_005397 DETD (1113) 37,8 SADETDGN
SNRP70: small nuclear ribonucleoprotein 70 kDa polypeptide
(RNP antigen)
NP_003080 DGPD (341) 3,451 GPDGPDGP
SPTBN1: spectrin, beta, non-erythrocytic 1 NP_003119 DEVD (1457) 100 STDEVDSK
SPTBN1: spectrin, beta, non-erythrocytic 2 NP_003119 ETVD (2146) 1,428 MAETVDTS
VIM: vimentin NP_003371 DSVD (85) 30,6 KGDEVDGV
amino acid sequence.
Theboldprintedaminoacidsintheextendedclevagesiteindicatehitsdetectedbythehighstringencyfilter.Numbersinbracketsindicateclevagesitepositioninthe
W212 Nucleic Acids Research, 2005, Vol. 33, Web Server issueaccordance with the results of Stennicke et al. (15). Absent
amino acids included the charged residues R, E, H, K and the
large residues Q, I, L, M, F, W and Y.
WithGraBCasweprovideapositionspeciﬁcscoringscheme
forthepredictionofcleavagesitesforgranzymeBandcaspases
1–9. GraBCas offers an easy to use, concise user interface in
register card format. The design of GraBCas speciﬁcally
acknowledged the high variability of cleavage site recognition
sequences. We validated our tool by scoring known substrates
and demonstrated its usefulness for protein sequence analysis.
GraBCas may contribute to a more comprehensive knowledge
of caspase and granzyme B substrates and a better understand-
ing of the biological roles of these enzymes.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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Table 4. Analysis of cleavage sites of known non-substrates of granzyme B with GraBCas
Granzyme B non-substrate Acc_number Best hit Score by GraBCas
TRIM21: 52 kD Ro/SSA autoantigen NP_003132 LDPD (294) 1,0296
SSA2: 60 kD Ro/SSA autoantigen NP_004591 VTTD (427) 1,4688
XRCC5: ATP-dependent DNA helicase II Ku80 NP_066964 FGTD (62) 0,3113856
VCL: vinculin isoform VCL NP_003364 LQSD (98) 0,3167424
VCL: vinculin isoform meta-VCL NP_054706 LQSD (98) 0,3167424
TUBB2: tubulin, beta 2 NP_001060 VISD (26) 0,0376
CRP: C-reactive protein, pentraxin-related NP_000558 LSPD (187) 1,5444
SERPINA1: serine (or cysteine) proteinase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin), member 1
NP_000286 LAED (26) 0,2291328
SERPINA1: serine (or cysteine) proteinase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin), member 1
NP_001002235 LAED (26) 0,2291328
SERPINA1: serine (or cysteine) proteinase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin), member 1
NP_001002236 LAED (26) 0,2291328
GSTA1: glutathione S-transferase A1 NP_665683 VEID (61) 0,8
PYGB: brain glycogen phosphorylase NP_002853 IEED (129) 28,8
TF: transferring NP_001054 VTLD (82) 0,2592
LTF: lactotransferrin NP_002334 VTLD (79) 0,2592
LYZ: lysozyme precursor NP_000230 RSTD (71) 0,0161568
ORM1: orosomucoid 1 precursor NP_000598 LAFD (133) 0,1145664
F2: coagulation factor II precursor (Thrombin B-chain) NP_000497 LDED (306) 0,2965248
Numbers in brackets indicate cleavage site position in the amino acid sequence.
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